Registration Options

Activity Dates: 03/07/2018-09/07/2018

This recertification course is closed. Check the availability of the latest recertification products.

Target Audience

This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and healthcare providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.

Content

The articles selected by CPNP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Patient Management, Domain 2: Information Management, Domain 3: Health Policy and Practice Management.

The Literature Analysis is a self-study, online only, application-based continuing pharmacy education (CPE) activity that releases March 7, 2018. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. The Literature Analysis includes:

  • Electronic access to all required journal articles needed to prepare for the online assessment.
  • For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination.
  • Access to the CPNP testing center with exam submission due by or on September 7, 2018.

Course Requirements

To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the recertification education.
  2. Complete an online assessment on or before the deadline of September 7, 2018.
  3. Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
  4. Partial credit is not available for individual topics within the Literature Analysis programming; it is either all 10 hours of Literature Analysis programming credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (78%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Your ACPE credit will be submitted directly to CPE Monitor within 48 hours after the official exam review and minimum passing score determination (4 weeks after close date) as long as you have provided the relevant information in your profile. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.

Learning Objectives

Article Number Topic Article and Learning Objectives
1 Design/Methodology

Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407- 411. DOI: 10.1111/ijcp.12142. PubMed PMID: 23574101.

AND

Vázquez GH, Holtzman JN, Tondo L, Baldessarini RJ. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183:258-62. DOI: 10.1016/j.jad.2015.05.016. PubMed PMID: 26042634.

  1. Determine the most appropriate statistical measurement necessary to interpret clinically significant real-world scenarios.
  2. Calculate NNT, NNH, and LHH using the outcomes reported in a clinical trial.
  3. Determine the clinical significance of results presented in a research article based on the number needed to treat (NNT) and/or number needed to harm (NNH).
  4. Develop evidence-based recommendations for other health care providers based on clinically significant trial results.
2 Education Methods for Patients and the Public

Werremeyer A, Skoy E, Aalgaard Kelly G. Medication Experience of Psychotropic Medications through Photovoice. Qualitative Health Research. Published online March 1, 2017.

  1. Evaluate the potential benefits of photovoice as a communication tool between patients and healthcare providers.
  2. Assess the limitations of the study on the generalizability of the use of photovoice in clinical practice.
  3. Employ photovoice as a tool for patients to educate providers about their medication experience.
3 Foster Care

Texas Department of Family and Protective Services, The University of Texas at Austin College of Pharmacy. Psychotropic Medication Utilization Parameters for Children and Youth in Foster Care 5th Version. [Online]. 2016 Jul [cited 2017 Jul 18]; Available from: URL: http://www.dfps.state.tx.us/Child_Protection/Medical_Services/documents/reports/2016-03_Psychotropic_Medication_Utilization_Parameters_for_Foster_Children.pdf

  1. Modify a patient’s treatment regimen following the general principles for use of non-pharmacologic and pharmacologic interventions in children and adolescents.
  2. Assess the appropriateness of off-label use of psychotropic medication in children and adolescents.
  3. Identify children and adolescents who qualify for a further review of their psychotropic medication regimen.
4 Info Sources/Technology

Myers K, Stoep AV, Zhou C, McCarty CA, Katon W. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54(4):263-74. DOI: 10.1016/j.jaac.2015.01.009. PubMed PMID: 25791143.

  1. Explain the results of this study with regard to the effectiveness of a telemental health service for treating attention-deficit/hyperactivity disorder (ADHD).
  2. Assess the limitations that affect the generalizability of this community-based randomized controlled trial evaluating the use of telehealth service for treating ADHD
  3. Develop evidence-based recommendations for telemental health services when given patient cases.
5 Marijuana

Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology. 2015;40(11):2489-98. DOI: 10.1038/npp.2015.108. PubMed PMID: 25881117.

  1. Predict how administration of naltrexone affects the reinforcing, subjective, and psychomotor effects of cannabis.   
  2. Apply the results of this trial to patients who use cannabis regularly.
  3. Analyze the safety and tolerability of naltrexone in patients who use cannabis daily.
6 Metabolic Guidelines

Cooper SJ, Reynolds GP, Barnes TRE, England E, Haddad PM, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717-48. DOI: 10.1177/0269881116645254. PubMed PMID: 27147592.

  1. Discuss the scope and development methods of the British Association for Psychopharmacology (BAP) guidelines on the management of weight gain, metabolic disturbances, and cardiovascular risk associated with antipsychotic drug treatment.
  2. Develop policies to optimize the monitoring and management of metabolic side effects associated with antipsychotic medications.
  3. Analyze recommendations made in the guidelines regarding interventions for the prevention and management of antipsychotic-induced weight gain and diabetes.
  4. Apply recommendations from the guidelines to patient cases encountered in clinical practice.
7 Nicotine-Hallmark Trial

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20. DOI: 10.1016/S0140-6736(16)30272-0. PubMed PMID: 27116918.

The Recertification Editorial Board generally avoids using industry-sponsored trials for our literature analysis product. In this case, this study was FDA-mandated and the investigators received other funding from non-industry sources. In addition, the findings from this study are both scientifically and clinically important.

  1. Analyze the study results for the effects of varenicline, bupropion, and the nicotine patch on neuropsychiatric symptoms.
  2. Evaluate the landmark clinical trial, Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), for application in clinical practice.
  3. Develop policies and procedures to optimize tobacco cessation treatment and monitoring.
8 Traumatic Brain Injury

Ponsford J, Lee NK, Wong D, McKay A, Haines K, Alway Y, et al. Efficacy of motivational interviewing and cognitive behavioral therapy for anxiety and depression symptoms following traumatic brain injury. Psychol. Med. 2016;46(05):1079- 1090. DOI: 10.1017/S0033291715002640. PubMed PMID: 26708017.

  1. Determine whether motivational interviewing is effective for treating anxiety and depressive symptoms after traumatic brain injury.
  2. Examine factors associated with efficacy of adapted cognitive behavioral therapy for treating anxiety and depressive symptoms after traumatic brain injury.
  3. Evaluate the limitations of the study methods using motivational interviewing for the treatment of depression and anxiety following traumatic brain injury.
9 Treatment Resistant Depression

Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404- 2412. DOI: 10.1016/S0140-6736(15)00308-6.

  1. Assess patients for appropriateness of aripiprazole augmentation in treatment resistant depression in late life.
  2. Identify efficacy and safety parameters of aripiprazole for augmentation pharmacotherapy of treatment resistant depression in late life.
  3. Design a pharmacotherapy treatment and monitoring plan using aripiprazole for a patient with treatment resistant depression in late life.

Continuing Education Credit and Disclosures

Activity Dates: 03/07/2018-09/07/2018
ACPE Contact Hours: 10
ACPE Number: 0284-0000-18-046-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.

CPNP will report credits earned into CPE Monitor within 48 hours after successful exam completion. Recertification credit will be reported after official exam review and cut-off score determination occurs (within 4 weeks of close date for course). ACPE transcripts reflecting CPE Monitor reporting are available at cpnp.org/mycpnp/transcript/acpe. You can access your BCPP Recertification transcript at cpnp.org/bcpp/transcript. This user-friendly transcript provides real-time access to a listing of the BCPP Recertification programming you have successfully completed in your current 7-year cycle along with your BCPP number and links to other BCPP Recertification resources.